Abbott licenses biomarkers for use in differentiating aggressive from nonaggressive prostate cancer
Abbott announced today it has acquired an exclusive license for several novel biomarkers from Stanford University for use in developing a molecular diagnostic test that could satisfy a longstanding unmet medical need: differentiating aggressive from nonaggressive prostate cancer.
A prostate cancer protein has been identified that could lead to new diagnostic tests and treatments.